(Total Views: 584)
Posted On: 03/02/2022 8:36:17 PM
Post# of 153887
Totally agree.
Would also suggest that at this juncture .50 is totally ridiculous & should not be the foundation for any negotiations. Nor should a bunch of outstanding warrants.
As CX suggested, Amarex debacle ( & NP oversteps) are about to be behind us. Idk about tomorrow, but I'm cool with it.
We are likely to crush it in Brazil critical ( NO one else has). Brazil moderate/severe(not the one I am excited about- just another feather) will IMHO be of great help in LH's protocol & we are already there, so why not do that trial there?
I will agree that EUA 's for covid will be tougher EXCEPT for critical, where NO one else is close. But even minus EUA, credibility & validation will move pps significantly.
This along with properly filed HIV BLA will push us to uplist & institutional investment long before revenue.
Add HIV 700 & added survival in cancer & I would feel kindof stupid for selling at a discount.
We need only to get pps to a couple bucks & authorized shares fund just about anything we want to do short-term.
The company has way better prospects today than when the warrants were bought. But no worries, there is no sh*tty deal on the horizon. We will clean the slate, settle our differences & move this forward to the point that NO shareholder gets srewed & maybe we ALL prosper.
Would also suggest that at this juncture .50 is totally ridiculous & should not be the foundation for any negotiations. Nor should a bunch of outstanding warrants.
As CX suggested, Amarex debacle ( & NP oversteps) are about to be behind us. Idk about tomorrow, but I'm cool with it.
We are likely to crush it in Brazil critical ( NO one else has). Brazil moderate/severe(not the one I am excited about- just another feather) will IMHO be of great help in LH's protocol & we are already there, so why not do that trial there?
I will agree that EUA 's for covid will be tougher EXCEPT for critical, where NO one else is close. But even minus EUA, credibility & validation will move pps significantly.
This along with properly filed HIV BLA will push us to uplist & institutional investment long before revenue.
Add HIV 700 & added survival in cancer & I would feel kindof stupid for selling at a discount.
We need only to get pps to a couple bucks & authorized shares fund just about anything we want to do short-term.
The company has way better prospects today than when the warrants were bought. But no worries, there is no sh*tty deal on the horizon. We will clean the slate, settle our differences & move this forward to the point that NO shareholder gets srewed & maybe we ALL prosper.
(6)
(0)
